Septerna
Septerna Inc is an American clinical-stage biopharmaceutical enterprise focused on discovering and developing oral small molecule drugs targeting G protein-coupled receptors (GPCRs). The company utilizes its proprietary Native Complex Platform to isolate and stabilize functional GPCR targets, advancing pipeline candidates for endocrinology, immunology, and metabolic disorders. Principal revenue is driven through research collaboration upfront fees, clinical milestone payments, and development capital raised ahead of commercialization. Core end markets encompass endocrinology specialty clinics, immunology research centers, and biopharmaceutical partners globally. Septerna holds an innovative position in the biopharmaceutical sector for structure-guided GPCR small molecule drug discovery. The company is headquartered in South San Francisco, California, and its common stock trades on the Nasdaq Global Market.
3 of the funds FundTelligence covers report a position in Septerna.
- Legal name
- SEPTERNA
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
Funds holding Septerna
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.14 % (full portfolio disclosed, October 2026)
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.1 % (full portfolio disclosed, September 2026)
- Nordea Internationale aktier — Nordea Funds · 0.01 % (full portfolio disclosed, September 2026)